[go: up one dir, main page]

DK2858985T3 - Krystallinske former af en androgen receptormodulator - Google Patents

Krystallinske former af en androgen receptormodulator Download PDF

Info

Publication number
DK2858985T3
DK2858985T3 DK13800681.2T DK13800681T DK2858985T3 DK 2858985 T3 DK2858985 T3 DK 2858985T3 DK 13800681 T DK13800681 T DK 13800681T DK 2858985 T3 DK2858985 T3 DK 2858985T3
Authority
DK
Denmark
Prior art keywords
theta
thioxo
oxo
fluoro
trifluoromethylpyridin
Prior art date
Application number
DK13800681.2T
Other languages
English (en)
Inventor
Nicholas D Smith
Mark R Herbert
Ouathek Ouerfelli
Anna Dilhas
Original Assignee
Aragon Pharmaceuticals Inc
Sloan Kettering Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49712550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2858985(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc, Sloan Kettering Inst Cancer Res filed Critical Aragon Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2858985T3 publication Critical patent/DK2858985T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Claims (15)

1. Krystallinsk Form B af 4-[7-(6-cyano-5-trifluormethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluor-N-methylbenzamide der er kendetegnet ved at have mindst én af: (a) et røntgenpulverdiffraktions-(XRPD)-mønster det samme som vist i Figur 2; (b) et røntgenpulverdiffraktions-(XRPD)-mønster med karakteristiske toppe ved 12,1±0,1° 2-Theta, 16,0±0,1° 2-Theta, 16,7±0,1° 2-Theta, 20,1±0,1° 2-Theta, 20,3±0,1° 2-Theta; (c) enhedscelleparametre lig med følgende ved -173°C:
(d) det samme røntgenpulverdiffraktions-(XRPD)-mønster som (a) eller (b) efter lagring ved 40°C og 75% RH i mindst en uge; eller (e) det samme røntgenpulverdiffraktions-(XRPD)-mønster som (a) eller (b) efter lagring ved 25°C og 92% RH i 12 dage.
2. Krystallinsk form ifølge krav 1, kendetegnet ved at have mindst én af: (f) et DSC termogram magen til det som beskrevet i Figur 11; (g) et termogravimetrisk analyse (TGA) termogram magen til det som beskrevet i Figur 11; eller (h) et DSC termogram med en endoterm med en starttemperatur ved 194°C.
3. Krystallinsk form ifølge krav 1 eller krav 2, hvor den krystallinske form har et røntgenpulverdiffraktions-(XRPD)-mønster med karakteristiske toppe ved 12,1±0,1° 2-Theta, 16,0±0,1° 2-Theta, 16,7±0,1° 2-Theta, 20,1±0,1° 2-Theta, 20,3±0,1° 2-Theta.
4. Krystallinsk form ifølge et hvilket som helst af kravene 1-3, hvor den krystallinske form har et røntgenpulverdiffraktions-(XRPD)-mønster, det samme som vist i Figur 2.
5. Krystallinsk form ifølge et hvilket som helst af kravene 1-4, hvor den krystallinske form har enhedscelleparametre lig med følgende ved -173°C:
6. Krystallinsk form ifølge et hvilket som helst af kravene 1-5, hvor den krystallinske form er ikke-solvatiseret.
7. Farmaceutisk sammensætning omfattende 4-[7-(6-cyano-5-trifluormethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluor-N-methylbenzamid og mindst én yderligere bestanddel valgt fra farmaceutisk acceptable bærere, fortyndingsmidler og excipienser, hvor 4-[7-(6-cyano-5- trifluormethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluor-N-methylbenzamidet i den farmaceutiske sammensætning omfatter krystallinsk Form B ifølge et hvilket som helst af kravene 1-6.
8. Farmaceutisk sammensætning ifølge krav 7, hvor den farmaceutiske sammensætning er i en form der er egnet til oral administration til et pattedyr.
9. Farmaceutisk sammensætning ifølge krav 8, hvor den farmaceutiske sammensætning er i en oral fast doseringsform.
10. Farmaceutisk sammensætning ifølge et hvilket som helst af kravene 7-9, hvor den farmaceutiske sammensætning omfatter 0,5 mg til 1000 mg krystallinsk 4-[7-(6-cyano-5-trifluormethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluor-N-methylbenzamid.
11. Farmaceutisk sammensætning ifølge et hvilket som helst af kravene 7-10 til anvendelse i behandlingen af prostatacancer hos et pattedyr.
12. Farmaceutisk sammensætning til anvendelse ifølge krav 11, hvor prostatacanceren er hormonfølsom prostatacancer eller hormon-refraktorisk prostatacancer.
13. Krystallinsk form af 4-[7-(6-cyano-5-trifluormethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluor-N-methylbenzamid ifølge et hvilket som helst af kravene 1-6 til anvendelse i behandlingen af prostatacancer hos et menneske.
14. Krystallinsk form til anvendelse ifølge krav 13, hvor prostatacanceren er hormonresistent prostatacancer eller hormon-refraktorisk prostatacancer.
15. Farmaceutisk sammensætning ifølge krav 8, hvor pattedyret er et menneske.
DK13800681.2T 2012-06-07 2013-06-04 Krystallinske former af en androgen receptormodulator DK2858985T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656888P 2012-06-07 2012-06-07
PCT/US2013/044116 WO2013184681A1 (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator

Publications (1)

Publication Number Publication Date
DK2858985T3 true DK2858985T3 (da) 2018-05-28

Family

ID=49712550

Family Applications (3)

Application Number Title Priority Date Filing Date
DK13800681.2T DK2858985T3 (da) 2012-06-07 2013-06-04 Krystallinske former af en androgen receptormodulator
DK18157435.1T DK3348553T3 (da) 2012-06-07 2013-06-04 Krystallinske former af en androgen receptormodulator
DK19169275.5T DK3533792T3 (da) 2012-06-07 2013-06-04 Krystallinske former af en androgenreceptormodulator

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK18157435.1T DK3348553T3 (da) 2012-06-07 2013-06-04 Krystallinske former af en androgen receptormodulator
DK19169275.5T DK3533792T3 (da) 2012-06-07 2013-06-04 Krystallinske former af en androgenreceptormodulator

Country Status (45)

Country Link
US (9) US9481663B2 (da)
EP (4) EP3533792B1 (da)
JP (3) JP6182209B2 (da)
KR (2) KR102062024B1 (da)
CN (3) CN104619692A (da)
AU (3) AU2013271751B2 (da)
BR (1) BR112014030678A2 (da)
CA (4) CA2875767C (da)
CL (1) CL2014003331A1 (da)
CO (1) CO7240407A2 (da)
CR (2) CR20190331A (da)
CY (4) CY1120393T1 (da)
DK (3) DK2858985T3 (da)
EA (3) EA028791B1 (da)
EC (1) ECSP14030098A (da)
ES (3) ES2875932T3 (da)
FR (1) FR21C1050I2 (da)
GT (1) GT201400283A (da)
HK (2) HK1210175A1 (da)
HR (3) HRP20180902T1 (da)
HU (4) HUE054595T2 (da)
IL (5) IL320522A (da)
IN (1) IN2014DN10084A (da)
LT (4) LT3533792T (da)
LU (1) LUC00236I2 (da)
ME (2) ME03815B (da)
MX (1) MX356754B (da)
MY (1) MY187500A (da)
NI (1) NI201400142A (da)
NL (1) NL301144I2 (da)
NO (1) NO2021046I1 (da)
NZ (2) NZ702203A (da)
PE (3) PE20200725A1 (da)
PH (2) PH12014502714A1 (da)
PL (3) PL3533792T3 (da)
PT (3) PT2858985T (da)
RS (3) RS57370B1 (da)
SG (3) SG10201610248SA (da)
SI (3) SI3533792T1 (da)
SM (3) SMT202100355T1 (da)
TR (1) TR201808939T4 (da)
TW (1) TWI532732B (da)
UA (2) UA115665C2 (da)
WO (1) WO2013184681A1 (da)
ZA (1) ZA201500076B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119015A2 (en) 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
AP2014007657A0 (en) 2011-12-16 2014-05-31 Olema Pharmaceuticals Inc Novel benzopyran compounds, compositions and uses thereof
US9481663B2 (en) 2012-06-07 2016-11-01 Aragon Pharmaceuticals, Inc. Crystalline forms of an androgen receptor modulator
ES2892029T3 (es) 2012-09-11 2022-02-01 Medivation Prostate Therapeutics Llc Formulaciones de enzalutamida
UA117663C2 (uk) 2012-09-26 2018-09-10 Арагон Фармасьютікалз, Інк. Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
WO2016029776A1 (en) * 2014-08-26 2016-03-03 Astar Biotech Llc Protein kinase inhibitors
MA41107B1 (fr) * 2014-12-05 2025-01-31 Aragon Pharmaceuticals, Inc. Compositions anti-cancéreuses
LT3226843T (lt) 2014-12-05 2021-08-10 Aragon Pharmaceuticals, Inc. Priešvėžinės kompozicijos
PT3226842T (pt) 2014-12-05 2020-12-23 Aragon Pharmaceuticals Inc Composições anticancerígenas
MX2017008050A (es) 2014-12-19 2018-01-18 Lutron Electronics Co Accesorio de iluminacion multicanal que tiene controladores de diodo emisor de luz.
AR108489A1 (es) 2016-06-03 2018-08-29 Aragon Pharmaceuticals Inc Composiciones antineoplásicas
WO2018112001A1 (en) 2016-12-13 2018-06-21 Watson Laboratories Inc. Solid state forms of apalutamide
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2019135254A1 (en) 2018-01-02 2019-07-11 Mylan Laboratories Limited Apalutamide polymorphs and their preparation thereof
WO2019242439A1 (zh) * 2018-06-20 2019-12-26 苏州科睿思制药有限公司 Arn-509的晶型及其制备方法和用途
WO2020049598A2 (en) 2018-09-08 2020-03-12 Cipla Limited Apalutamide polymorphs
IT201900003839A1 (it) 2019-03-15 2020-09-15 Olon Spa Sintesi di apalutamide amorfa stabile
WO2020234817A1 (en) * 2019-05-21 2020-11-26 Laurus Labs Limited Polymorphic forms of apalutamide and its preparation thereof
IT201900010593A1 (it) 2019-07-01 2021-01-01 Dipharma Francis Srl Forma cristallina di un inibitore di recettori degli androgeni
EP4017848A1 (en) * 2019-08-22 2022-06-29 Dr. Reddy's Laboratories Ltd. Process for the preparation of apalutamide
IT201900015974A1 (it) 2019-09-10 2021-03-10 Olon Spa Apalutamide cristallina stabile in forma pura e processo per la sua preparazione
CN110590740A (zh) * 2019-09-20 2019-12-20 武汉大学 一种阿帕鲁胺化合物及其药物制剂
CN116034101A (zh) 2020-09-04 2023-04-28 斯索恩有限公司 制备阿帕鲁胺的改进方法
CN112679468A (zh) * 2021-01-05 2021-04-20 四川科伦药物研究院有限公司 阿帕他胺的晶体形式、制备方法和用途
WO2023143090A1 (zh) * 2022-01-25 2023-08-03 成都苑东生物制药股份有限公司 一种阿帕他胺溶剂化物新晶型及其制备方法
CN115536634B (zh) * 2022-10-17 2024-06-11 上海博悦生物科技有限公司 一种阿帕他胺的合成方法
CN116332907A (zh) * 2023-03-16 2023-06-27 奥锐特药业股份有限公司 一种无定形阿帕他胺的制备方法
WO2025153768A1 (en) * 2024-01-18 2025-07-24 Nanoform Finland Oyj Composition comprising crystalline nanosized apalutamide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
LT2656841T (lt) * 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
MX2008012492A (es) * 2006-03-29 2008-12-12 Univ California Compuestos de diariltiohidantoina.
WO2008119015A2 (en) * 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
AU2011218173C1 (en) * 2010-02-16 2015-04-16 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
US9481663B2 (en) 2012-06-07 2016-11-01 Aragon Pharmaceuticals, Inc. Crystalline forms of an androgen receptor modulator
WO2019242439A1 (zh) 2018-06-20 2019-12-26 苏州科睿思制药有限公司 Arn-509的晶型及其制备方法和用途

Also Published As

Publication number Publication date
KR102195916B1 (ko) 2020-12-30
AU2017279807A1 (en) 2018-01-25
AU2017200298B2 (en) 2017-09-28
JP6182209B2 (ja) 2017-08-16
US20170001977A1 (en) 2017-01-05
US20200354335A1 (en) 2020-11-12
CN113135892A (zh) 2021-07-20
RS61988B1 (sr) 2021-07-30
WO2013184681A1 (en) 2013-12-12
FR21C1050I2 (fr) 2024-05-24
KR20150021993A (ko) 2015-03-03
LTPA2021525I1 (da) 2021-11-25
LT3348553T (lt) 2020-09-25
PL3533792T3 (pl) 2021-11-29
PL3348553T3 (pl) 2021-02-08
EA201492272A1 (ru) 2015-05-29
CA3055660A1 (en) 2013-12-12
SI2858985T1 (sl) 2018-12-31
PH12014502714B1 (en) 2015-02-02
EA033956B1 (ru) 2019-12-13
ES2809738T3 (es) 2021-03-05
ES2670683T3 (es) 2018-05-31
HUE050357T2 (hu) 2020-11-30
SG10201610248SA (en) 2017-02-27
US10766875B2 (en) 2020-09-08
EP2858985A4 (en) 2016-05-25
CR20190331A (es) 2019-11-12
HK1210175A1 (en) 2016-04-15
ME03081B (me) 2019-01-20
ME03815B (me) 2021-04-20
HRP20180902T1 (hr) 2018-08-24
FR21C1050I1 (fr) 2021-12-10
NL301144I2 (nl) 2025-03-20
DK3348553T3 (da) 2020-07-27
US20190241539A1 (en) 2019-08-08
EP2858985B1 (en) 2018-04-18
KR20190132543A (ko) 2019-11-27
CY2021032I2 (el) 2022-03-24
CA3008345A1 (en) 2013-12-12
DK3533792T3 (da) 2021-06-28
TW201402561A (zh) 2014-01-16
CN104619692A (zh) 2015-05-13
CA3114726A1 (en) 2013-12-12
US10934271B2 (en) 2021-03-02
PT3533792T (pt) 2021-06-07
US12018008B2 (en) 2024-06-25
UA115665C2 (uk) 2017-12-11
ZA201500076B (en) 2016-10-26
US10526310B2 (en) 2020-01-07
MX2014015005A (es) 2015-09-04
LT3533792T (lt) 2021-07-26
IL267608A (en) 2019-08-29
JP2018141009A (ja) 2018-09-13
PE20200725A1 (es) 2020-07-21
LT2858985T (lt) 2018-09-25
US20210163441A1 (en) 2021-06-03
EP3348553B1 (en) 2020-07-08
NO2021046I1 (no) 2021-11-02
NZ702203A (en) 2016-09-30
SI3348553T1 (sl) 2020-11-30
JP2015518890A (ja) 2015-07-06
EA201791592A1 (ru) 2018-01-31
US20250092011A1 (en) 2025-03-20
NZ717683A (en) 2018-04-27
SG11201408140QA (en) 2015-01-29
EP3533792B1 (en) 2021-05-05
EP3533792A1 (en) 2019-09-04
MX356754B (es) 2018-06-11
HRP20210909T1 (hr) 2021-09-03
SMT202100355T1 (it) 2021-07-12
IN2014DN10084A (da) 2015-08-21
US20180258067A1 (en) 2018-09-13
TWI532732B (zh) 2016-05-11
GT201400283A (es) 2017-07-03
RS57370B1 (sr) 2018-08-31
IL259738A (en) 2018-07-31
AU2013271751A1 (en) 2014-12-18
US9994545B2 (en) 2018-06-12
HUE054595T2 (hu) 2021-09-28
MY187500A (en) 2021-09-24
CO7240407A2 (es) 2015-04-17
EA028791B1 (ru) 2017-12-29
IL236055A0 (en) 2015-02-01
PH12016501470B1 (en) 2021-12-10
ES2875932T3 (es) 2021-11-11
PT2858985T (pt) 2018-07-10
CA3008345C (en) 2019-10-22
CA2875767A1 (en) 2013-12-12
US10556882B2 (en) 2020-02-11
LUC00236I2 (da) 2025-02-03
EP3348553A1 (en) 2018-07-18
US20200115361A1 (en) 2020-04-16
PH12016501470A1 (en) 2017-07-10
HUS2100047I1 (hu) 2021-11-29
AU2013271751B2 (en) 2017-02-23
ECSP14030098A (es) 2016-01-29
CY1124831T1 (el) 2022-03-24
CN105693692A (zh) 2016-06-22
EA201992010A1 (ru) 2020-01-24
CA2875767C (en) 2018-08-14
BR112014030678A2 (pt) 2017-06-27
US9481663B2 (en) 2016-11-01
SI3533792T1 (sl) 2021-11-30
UA123142C2 (uk) 2021-02-24
CL2014003331A1 (es) 2016-03-04
CY1120393T1 (el) 2019-07-10
PE20200795A1 (es) 2020-08-10
CR20140549A (es) 2015-04-06
US20190330182A1 (en) 2019-10-31
AU2017279807B2 (en) 2018-11-08
IL267608B1 (en) 2025-06-01
LTC3533792I2 (da) 2024-07-10
US10308630B2 (en) 2019-06-04
JP6345821B2 (ja) 2018-06-20
PE20150631A1 (es) 2015-05-11
TR201808939T4 (tr) 2018-07-23
IL267608B2 (en) 2025-10-01
US20150133481A1 (en) 2015-05-14
IL275413A (en) 2020-07-30
HRP20201387T1 (hr) 2020-11-27
HUE038082T2 (hu) 2018-09-28
KR102062024B1 (ko) 2020-01-03
SMT202000496T1 (it) 2020-11-10
PH12014502714A1 (en) 2015-02-02
EP2858985A1 (en) 2015-04-15
AU2017200298A1 (en) 2017-02-02
SMT201800311T1 (it) 2018-07-17
PT3348553T (pt) 2020-09-28
NI201400142A (es) 2016-12-02
HK1226066A1 (zh) 2017-09-22
IL320522A (en) 2025-06-01
RS60617B1 (sr) 2020-09-30
IL259738B (en) 2021-06-30
JP2017178923A (ja) 2017-10-05
EP3922629A1 (en) 2021-12-15
CY1123427T1 (el) 2021-12-31
PL2858985T3 (pl) 2018-09-28
CY2021032I1 (da) 2022-03-24
SG10201610249TA (en) 2017-02-27

Similar Documents

Publication Publication Date Title
US20250092011A1 (en) Crystalline Forms Of An Androgen Receptor Modulator
HK40068033A (en) Crystalline forms of an androgen receptor modulator